期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

英夫利昔单抗治疗类风湿关节炎和强直性脊柱炎的参考意见 被引量：7

原文传递
导出
摘要 类风湿关节炎（rheumatoid arthritis，RA）和强直性脊柱炎（ankylosing spondlitis，AS）是一种病因尚未清楚的炎性关节病。在其发病过程中，肿瘤坏死因子（TNF）-α等炎症因子扮演了至关重要的角色。目前多种TNF-α拮抗剂已经在欧美国家上市，主要用于RA和AS的治疗。英夫利昔单抗（infliximab，商品名类克）作为中国最早上市的TNF-α单克隆抗体，在国外已经上市十年余，大量的临床证据为中国的应用提供了宝贵的经验。2008年3月2日国内风湿界的部分专家就英夫利昔单抗在RA和AS中的临床应用、疗效、不良反应的监测和处理，参考国外的经验，
机构地区 英夫利昔单抗使用参考意见专家组
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2009年第4期279-282,共4页 Chinese Journal of Rheumatology
关键词 类风湿关节炎 强直性脊柱炎 单抗治疗 (TNF)-Α TNF-α 肿瘤坏死因子 炎性关节病 单克隆抗体
分类号 R593.22 [医药卫生—内科学] R593.23 [医药卫生—内科学]
  • 相关文献

参考文献19

  • 1Arnett FC,Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324.
  • 2Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostie criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arihritis Rheum, 1984, 27:361 - 368.
  • 3St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum, 2004, 50: 3432-3443.
  • 4Smolen JS, van Der Heijde DM, St Clair EW, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum, 2006,54: 702-710.
  • 5Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum, 2004, 50: 1051-1065.
  • 6Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol, 2006, 24: 77-82.
  • 7Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to ctanercept: the opposite study. Ann Rheum Dis, 2007, 66: 893-899.
  • 8van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum, 2005, 52: 582-591.
  • 9Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study . Ann Rheum Dis, 2006, 65: 1631-1634.
  • 10Bassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin lnfec Dis, 2006, 43: 717-722.

同被引文献86

  • 1张莉芸,黄烽.生物制剂治疗强直性脊柱炎研究进展[J].中华风湿病学杂志,2005,9(2):112-115. 被引量：50
  • 2郝慧琴,黄烽,唐捷,邓小虎,张亚美,索塔林,方显峰.不同剂量重组人Ⅱ型肿瘤坏死因子受体-Fc融合蛋白治疗强直性脊柱炎疗效比较[J].中华风湿病学杂志,2007,11(4):202-205. 被引量：17
  • 3朱剑,黄烽,张莉芸,张江林,张奉春,候勇,余德恩.寻找预测强直性脊柱炎患者接受3次infliximab治疗后10周病情改善及复发的指标[J].中华风湿病学杂志,2007,11(5):288-292. 被引量：9
  • 4DOLLGADOS M, VAILDER H D. Ankylosing spondylitisi how should the disease be assessed[ J]. Best Pract Res Clin Rheumatol ,2004 ,16 :615 - 618.
  • 5VANDER H D, DIJKMANS B, GEUSENS P, et al. Efficacy and safety of infliximab in patients with ankylosing spendylltis:resuhs of a randomized placebo-controlled trial (ASSERT) [ J ]. Arthritis Rheum,2005,52:582 - 591.
  • 6GUIGNARD S, GOSSEC L, SALLIOT C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondy-larthropathy: a retrospective study [ J]. Ann Rheum Dis ,2006,65 : 1631 - 1634.
  • 7ANTONI C, BRAUN J. Side effects of anti-TNF therapy:current knowledge [ J ]. Clin Exp Rheumatlo, 2002, 20 : 152 - 157.
  • 8WALLIS R S, BRODER M S, WONG J Y, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists [ J ]. Clin Infect Dis, 2004,38 : 1261 - 1265.
  • 9INFLVLACHAKI E, PSATHAKIS K, TSINTIRIS K, et al. Delayed response to anti-tuberculosis treatment in a patient on infliximab[ J]. Respir Med, 2005, 99:648 - 652.
  • 10ASKLING J , FORED C M, BRANDT L ,et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosi: factor antagonists in Sweden [ J]. Arthritis Rheum, 2005, 52 : 1986 - 1992.

引证文献7

二级引证文献36

中华风湿病学杂志
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部